Poly ADP ribose polymerase (PARP) inhibitors, namely olaparib and talazoparib, approximately halved PFS in the OLYMPIAD and EMBRACA trials in patients with HER2-negative BC and BRCA germline mutations [87, 88]. Here, ERBB2 is linked to breast cancer.